Opinion|Videos|March 1, 2025
Current and Emerging Treatment Landscape of mHSPC
Jack Andrews MD; Eugene Cone, MD; and Arash Rezazadeh, MD, discuss how metastatic hormone-sensitive prostate cancer presents clinically, explore current treatment standards including combination therapies, evaluate emerging data from the ARANOTE trial on darolutamide efficacy, consider quality of life factors in treatment selection, and examine how novel therapeutic approaches may reshape future care pathways.
Advertisement
Episodes in this series
Timecodes
1:54 mHSPC and Imaging
4:57 Current SOC in mHSPC
10:15 Choosing Therapy in mHSPC
18:51 ARANOTE Trial in mHSPC
21:15 Experience With ARI
27:08 Emerging mHSPC Treatments
32:51 ARANOTE Subgroup Analysis
35:31 Future Outlook for mHSPC
Advertisement
Related to this article
Chad Ritch, MD, discusses differences between PSMA-PET imaging agents and the need for further evidence to guide clinical decision-making.
The final analysis confirmed PFS and response benefits in previously treated advanced clear cell renal cell carcinoma, but the OS difference did not cross the prespecified significance boundary.
Chad Ritch, MD, discusses how PSMA-PET informs patient management across different stages of the prostate cancer journey.
Topline results are expected in November 2026 ahead of a planned sBLA submission.
Alicia K. Morgans, MD, MPH, reviews promising prostate cancer findings from ESMO 2026,
A comprehensive guide to the top data in genitourinary oncology presented at ESMO 2026.
Brian I. Rini, MD, FASCO, explains why LITESPARK-012’s negative triplet results still offer lessons on drug delivery and building on first-line RCC doublets.
Topline results from the study are anticipated in the first half of 2027.
Advertisement
Advertisement
Trending on Urology Times
1
Belzutifan plus lenvatinib maintains PFS benefit vs cabozantinib in advanced ccRCC
2
Alicia Morgans, MD, MPH, highlights key prostate cancer data from ESMO 2026
3
Chad Ritch, MD, on using PSMA-PET to guide treatment decisions
4
Updated CAPItello-281 data show numerical OS benefit with capivasertib in PTEN-deficient mHSPC
5